While the beneficial effects of adiponectin signaling on mediating metabolic have been widely accepted44, our study provided the evidence of the potential therapeutical effects of an adiponectin-based peptide agonist on NASH and, particularly, the related fibrosis. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatohepatitis.